Enzolytics Inc (ENZC)

[foxi]

I looked at the example deal again, and I don't think what you said matches what ENZC is telling us.


From Supplemental Information - Supplemental Information published 7/11:
https://www.otcmarkets.com/otcapi/company/financial-report/376167/content

The management of BGEN and VIRO will continue to manage the two subs as wholly owned subsidiaries of SAGA

The issuance of the Purchase Shares to Company E will result in a 90% plus ownership position of Company S until the Purchase Shares are paid as a dividend to the shareholders of Company E.

[regarding any Make-Whole bonus shares] The additional shares would be allocated proportionately to the holders of Company E’s common shares on the declared dividend date.

After the dividend to Company E shareholders, there would be no assets or operations in Company E,

It appears ENZC is indeed attempting to sell all its tech, which has been disclosed in ENZC's prior OTC markets filings as being retained fully in ENZC subsidiaries BGEN and VIRO, to SAGA. The valuation of BGEN and VIRO is $450M, not $4.5B, which does come out to 15 cents a share.

BGEN and VIRO would become SAGA's wholly owned subsidiaries. Whoever's at the top of the chain at SAGA would ultimately control ENZC IP, licensing, partnerships, and operations, except for what SAGA delegates to BGEN and VIRO management (ENZC's current management team).

As the deal is currently proposed, ENZC would have no assets and no operations remaining after the acquisition. (Technically they'd have RobustoMed, which would have zero assets and need a new business plan.)

There's nothing implying Sagaliam would rename itself. Investors would collect dividend shares one time; they would not collect 10% revenue until the end of time.

I'd give you more than one post a day if I had the ability, would love to hear your additional thoughts.